Broadfin Capital LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Broadfin Capital LLC
CRD #156900
SEC #801-73567
CIK #0001511901
AUM
Employees 9 (56% Investors, 0% Brokers)
Fees
Minimum
Phone212-808-2460
Address300 Park Avenue
New York, NY 10022
Source [IAPD] [EDGAR] [Website]
Total AUM ($M)
20001600120080040002009201420192025
Fees and Compensation — Form ADV Part 2A (3/19/2020) [Brochure]
ITEM 5: FEES AND COMPENSATION

Compensation for Advisory Services.

The Investment Manager receives a quarterly management fee calculated at the annual rate of 2.0%
of the net assets of each investor of the Domestic Feeder Fund and the Offshore Feeder Fund (the
“Management Fee”). The Management Fee is paid quarterly in advance, based on the value of each
Investor’s account value as of the beginning of each quarter. The Management Fee is prorated for
any period that is less than a full quarter and is adjusted for contributions and withdrawals made
during the quarter.

In addition to management fees, Broadfin’s affiliate, Broadfin Advisors, LLC is entitled to receive
performance based compensation ranging from 17.5% to 20% of the net profits, including realized
and unrealized gains and losses, if any, of Investors of the Domestic Feeder Fund and the Offshore
Feeder Fund, subject to a loss carryforward.

The Management Fee and performance allocations are described in further detail in the offering
documents for the Domestic Feeder Fund and Offshore Feeder Fund.

Other Types of Expenses.

Expenses absorbed by the Investment Manager include but are not limited to: utilities, furniture and
fixtures, stationery, secretarial/internal administrative services, salaries, entertainment expenses,
employee insurance, and payroll taxes.

Fees, costs, and expenses, paid by the Funds include, but are not limited to: (1) the Management Fee;
(2) performance allocations; (3) Fund legal, compliance, audit, tax, accounting, portfolio
management/order management system costs, and administrator fees and expenses (including third
party accounting services); (4) fees of outside consultants, analysts or advisors Broadfin may engage
to provide advice related to portfolio investments; (5) brokerage commissions and securities
transaction costs; (6) custodial, transfer agent and distributions agent charges; (7) expenses relating
to insurance (including directors’ and officers’ insurance, errors and omission insurance, Fund
indemnification coverage and other similar policies); (8) taxes and other governmental charges, fees
and duties; (9) organizational expenses; (10) shareholder proxy voting services; (11) investment
expenses such as research fees and expenses (including research-related travel, food and lodging);
(12) interest on margin accounts and other indebtedness; (13) borrowing charges and dividend
expenses on securities sold short; (14) director’s fees and expenses; and (15) any other fees, costs,
expenses, and liabilities that are incurred by, or arise out of, the operation and activities of the Funds
or the purchase, sale or transmittal of Fund assets.

Each Feeder Fund will invest in the Master Fund on substantially the same terms and conditions and
therefore will generally be allocated a proportionate share of the Master Fund’s gains, losses and
expenses based on their interest in the Master Fund.

The Master Fund will incur brokerage fees. Please see Item 12 of this brochure for further discussion
of Broadfin’s brokerage practices.

Broadfin Capital, LLC – ADV Part 2A                                                                     5
Account Minimums and Types of Clients — Form ADV Part 2A (3/19/2020) [Brochure]
ITEM 7: TYPES OF CLIENTS

The Firm’s only clients are the Feeder Funds and the Master Fund, which are private investment
vehicles. Investors in the Funds may include individuals, investment companies, pooled investment
vehicles, pension and profit sharing plans, trusts, estates, governmental plans, endowments,
foundations, charitable organizations, corporations, insurance companies, limited partnerships,
commingled investment trusts, and other entities.

Investors in the Funds must generally be “accredited investors” as that term is defined in Rule 501 of
Regulation D of the Securities Act of 1933 and “qualified purchasers” within the meaning of Section
2(a)(51) and Rule 2a51-1 under the Investment Company Act of 1940.

Investors are required to commit or contribute certain minimum capital amounts to become Investors
of the Domestic Feeder Fund and Offshore Feeder Fund. Currently, the minimum required investment
is $1,000,000. This minimum amount is subject to change at the sole direction of the general partner
for the Domestic Feeder Fund and Board of Directors for the Offshore Feeder Fund.

Broadfin Capital, LLC – ADV Part 2A                                                                 7
Sector Form 13F Holdings Value ($B)
Biohaven Ltd 0.1
Alkermes PLC 0.0
Amarin Corp PLC UK 0.0
Staar Surgical Co 0.0
Genesis Biopharma Inc 0.0
Journey Medical Corp 0.0
Lantheus Holdings Inc 0.0
Aastrom Biosciences Inc 0.0
Sol-Gel Technologies Ltd 0.0
Camp Nine Inc 0.0
View All
Holdings by Sector ($B)
3.02.41.81.20.60.02011201420172021
Type Form D Funds Date Sold AUM
HF Broadfin Healthcare Master Fund Ltd 2012-02-14 739.5 M
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 3 739.5
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 3 739.5
By Discretionary
Discretionary 3 739.5
Non-Discretionary 0 0.0
Total 3 739.5
By Non-United States Persons
Non-United States Persons 200.3
United States Persons 539.3
Total 3 739.5
EDGAR Form CIK 2011 - 2026
13F-HR [0001511901]
3 [0001511901]
4 [0001511901]
SC 13D [0001511901]
SC 13G [0001511901]
Form 13D/13G Filer Form 13D/13G Subject Filed
Broadfin Capital LLC Retrophin Inc [2019-07-19]
Broadfin Capital LLC Eiger Biopharmaceuticals Inc [2019-06-14]
Broadfin Capital LLC Egalet Corp [2019-02-11]
Broadfin Capital LLC Aclaris Therapeutics Inc [2019-01-29]
Broadfin Capital LLC Neos Therapeutics Inc [2019-01-03]
Broadfin Capital LLC Avadel Pharmaceuticals PLC [2018-12-11]
Broadfin Capital LLC Sierra Oncology Inc [2018-09-07]
Broadfin Capital LLC ADMA Biologics Inc [2018-06-11]
Broadfin Capital LLC Teligent Inc [2018-05-01]
Broadfin Capital LLC Adamas Pharmaceuticals Inc [2018-04-24]
Broadfin Capital LLC Biodelivery Sciences International Inc [2018-04-10]
Broadfin Capital LLC Iovance Biotherapeutics Inc [2018-02-13]
Broadfin Capital LLC Arcturus Therapeutics Ltd [2018-02-13]
Broadfin Capital LLC La Jolla Pharmaceutical Co [2018-01-11]
Broadfin Capital LLC Egalet Corp [2018-01-03]
Broadfin Capital LLC Regulus Therapeutics Inc [2017-07-24]
Broadfin Capital LLC Cidara Therapeutics Inc [2017-07-13]
Broadfin Capital LLC Alphatec Holdings Inc [2017-03-29]
Broadfin Capital LLC Windtree Therapeutics Inc /DE/ [2017-02-10]
Broadfin Capital LLC Dextera Surgical Inc [2017-02-10]
Broadfin Capital LLC Mirati Therapeutics Inc [2017-01-09]
Broadfin Capital LLC Avadel Pharmaceuticals PLC [2017-01-06]
Broadfin Capital LLC Durect Corp [2016-11-21]
Broadfin Capital LLC Veracyte Inc [2016-11-04]
Broadfin Capital LLC Mirati Therapeutics Inc [2016-08-10]
Broadfin Capital LLC Aegerion Pharmaceuticals Inc [2016-06-22]
Broadfin Capital LLC QLT Inc/BC [2016-06-22]
Broadfin Capital LLC Aralez Pharmaceuticals Inc [2016-03-24]
Broadfin Capital LLC Nevro Corp [2016-03-01]
Broadfin Capital LLC Cardica Inc [2016-02-26]
Broadfin Capital LLC Lion Biotechnologies Inc [2016-02-11]
Broadfin Capital LLC Egalet Corp [2016-02-11]
Broadfin Capital LLC Raptor Pharmaceutical Corp [2016-01-28]
Broadfin Capital LLC Strongbridge Biopharma PLC [2016-01-13]
Broadfin Capital LLC Nexvet Biopharma PLC [2015-12-28]
Broadfin Capital LLC Aratana Therapeutics Inc [2015-11-03]
Broadfin Capital LLC Novadaq Technologies Inc [2015-10-29]
Broadfin Capital LLC Nevro Corp [2015-09-24]
Broadfin Capital LLC Antares Pharma Inc [2015-09-09]
Broadfin Capital LLC Cardica Inc [2015-09-04]
Broadfin Capital LLC Advaxis Inc [2015-08-12]
Broadfin Capital LLC SeaSpine Holdings Corp [2015-07-21]
Broadfin Capital LLC Medgenics Inc [2015-07-16]
Broadfin Capital LLC Recro Pharma Inc [2015-07-15]
Broadfin Capital LLC Ritter Pharmaceuticals Inc [2015-07-01]
Broadfin Capital LLC QLT Inc/BC [2015-06-25]
Broadfin Capital LLC Contrafect Corp [2015-06-17]
Broadfin Capital LLC Scynexis Inc [2015-05-27]
Broadfin Capital LLC Biodelivery Sciences International Inc [2015-05-20]
Broadfin Capital LLC Kempharm Inc [2015-04-29]
Broadfin Capital LLC Carbylan Therapeutics Inc [2015-04-14]
Broadfin Capital LLC OHR Pharmaceutical Inc [2015-04-07]
Broadfin Capital LLC Cardica Inc [2015-03-25]
Broadfin Capital LLC Ignyta Inc [2015-03-24]
Broadfin Capital LLC ADMA Biologics Inc [2015-03-19]
Broadfin Capital LLC Derma Sciences Inc [2015-03-18]
Broadfin Capital LLC Zogenix Inc [2015-03-18]
Broadfin Capital LLC BioLineRx Ltd [2015-03-16]
Broadfin Capital LLC Redhill Biopharma Ltd [2015-02-26]
Broadfin Capital LLC Biodel Inc [2015-02-17]
Broadfin Capital LLC Tonix Pharmaceuticals Holding Corp [2015-02-17]
Broadfin Capital LLC Catalyst Pharmaceutical Partners Inc [2015-02-13]
Broadfin Capital LLC Epirus Biopharmaceuticals Inc [2015-02-06]
Broadfin Capital LLC Alcobra Ltd [2015-01-16]
Broadfin Capital LLC Aegerion Pharmaceuticals Inc [2014-11-07]
Broadfin Capital LLC Titan Pharmaceuticals Inc [2014-10-10]
Broadfin Capital LLC Anthera Pharmaceuticals Inc [2014-10-03]
Broadfin Capital LLC Recro Pharma Inc [2014-09-15]
Broadfin Capital LLC Biota Pharmaceuticals Inc [2014-08-08]
Broadfin Capital LLC Cardica Inc [2014-07-24]
Broadfin Capital LLC Amphastar Pharmaceuticals Inc [2014-07-03]
Broadfin Capital LLC Oxygen Biotherapeutics Inc [2014-06-11]
Broadfin Capital LLC Emergent Biosolutions Inc [2014-05-19]
Broadfin Capital LLC Corium International Inc [2014-04-16]
Broadfin Capital LLC AMAG Pharmaceuticals Inc [2014-04-16]
Broadfin Capital LLC La Jolla Pharmaceutical Co [2014-04-16]
Broadfin Capital LLC Dipexium Pharmaceuticals Inc [2014-04-07]
Broadfin Capital LLC Recro Pharma Inc [2014-03-13]
Broadfin Capital LLC Pernix Therapeutics Holdings Inc [2014-03-06]
Broadfin Capital LLC MELA Sciences Inc /NY [2014-03-04]
Broadfin Capital LLC Eleven Biotherapeutics Inc [2014-02-19]
Broadfin Capital LLC Liberator Medical Holdings Inc [2014-02-03]
Broadfin Capital LLC Retrophin Inc [2014-01-17]
Broadfin Capital LLC Ampliphi Biosciences Corp [2014-01-03]
Broadfin Capital LLC Rigel Pharmaceuticals Inc [2013-12-27]
Broadfin Capital LLC Derma Sciences Inc [2013-12-20]
Broadfin Capital LLC Horizon Pharma Inc [2013-11-27]
Broadfin Capital LLC Alliqua Inc [2013-11-27]
Broadfin Capital LLC Discovery Laboratories Inc /DE/ [2013-10-17]
Broadfin Capital LLC Biodel Inc [2013-10-07]
Broadfin Capital LLC Celsus Therapeutics PLC [2013-10-04]
Broadfin Capital LLC Idera Pharmaceuticals Inc [2013-10-04]
Broadfin Capital LLC CAS Medical Systems Inc [2013-09-18]
Broadfin Capital LLC Tonix Pharmaceuticals Holding Corp [2013-08-14]
Broadfin Capital LLC Durect Corp [2013-05-14]
Broadfin Capital LLC Tetraphase Pharmaceuticals Inc [2013-03-27]
Broadfin Capital LLC Depomed Inc [2013-03-27]
Broadfin Capital LLC Cardica Inc [2013-03-19]
Broadfin Capital LLC RXI Pharmaceuticals Corp [2013-03-19]
Broadfin Capital LLC Biodelivery Sciences International Inc [2013-03-11]
Broadfin Capital LLC Ventrus Biosciences Inc [2013-02-04]
Broadfin Capital LLC AP Pharma Inc /DE/ [2012-12-31]
Broadfin Capital LLC Progenics Pharmaceuticals Inc [2012-12-10]
Broadfin Capital LLC Flamel Technologies Sa [2012-09-28]
Broadfin Capital LLC Solta Medical Inc [2012-08-14]
Broadfin Capital LLC Angiodynamics Inc [2012-05-22]
Broadfin Capital LLC Novadaq Technologies Inc [2012-04-10]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
LEI5493004SOHPILFJ75467
Form 3/4/5 Subject 2011 - 2026
Biodelivery Sciences International Inc
Broadfin Capital LLC
Kotler Kevin
Broadfin Healthcare Master Fund Ltd
Novelion Therapeutics Inc
Avadel Pharmaceuticals PLC
Aratana Therapeutics Inc
Corium International Inc
Societal CDMO Inc
Mirati Therapeutics Inc
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Biodelivery Sciences International Inc BDSI
Stock Options (right to buy) · derivative
2022-03-22 Disposed to issuer 7,500 $0.00
Biodelivery Sciences International Inc BDSI
Stock Options (right to buy) · derivative
2022-03-22 Disposed to issuer 85,760 $0.00
Biodelivery Sciences International Inc BDSI
Restricted Stock Units · derivative
2022-03-22 Disposed to issuer 22,685 $0.00
Biodelivery Sciences International Inc BDSI
Common Stock
2022-03-22 Other 7,588,395 $0.00
Biodelivery Sciences International Inc BDSI
Common Stock
2022-02-11 Conversion 2,422,222 $1.80 4,360,000
Biodelivery Sciences International Inc BDSI
Series B Convertible Preferred Stock · derivative
2022-02-11 Conversion 436 $10,000.00 4,360,000
Biodelivery Sciences International Inc BDSI
Restricted Stock Units · derivative
2022-01-27 Grant 15,369 $0.00
Biodelivery Sciences International Inc BDSI
Stock Options (right to buy) · derivative
2022-01-27 Grant 85,760 $0.00
Biodelivery Sciences International Inc BDSI
Restricted Stock Units · derivative
2022-01-27 Option exercise 7,684 $0.00
Biodelivery Sciences International Inc BDSI
Common Stock
2022-01-27 Option exercise 7,684 $0.00
Biodelivery Sciences International Inc BDSI
Common Stock
2021-11-19 Buy 100,000 $3.06 306,000
Biodelivery Sciences International Inc BDSI
Common Stock
2021-11-12 Buy 100,000 $3.20 320,000
Biodelivery Sciences International Inc BDSI
Common Stock
2021-11-05 Buy 257,800 $3.47 894,566
Biodelivery Sciences International Inc BDSI
Stock Options (right to buy) · derivative
2021-08-10 Conversion 15,000 $2.93 43,950
Biodelivery Sciences International Inc BDSI
Common Stock
2021-08-10 Option exercise 15,000 $2.93 43,950
Biodelivery Sciences International Inc BDSI
Common Stock
2021-08-06 Option exercise 30,000 $0.00
Biodelivery Sciences International Inc BDSI
Restricted Stock Units · derivative
2021-08-06 Option exercise 30,000 $0.00
Biodelivery Sciences International Inc BDSI
Common Stock
2021-05-13 Buy 50,000 $3.25 162,500
Biodelivery Sciences International Inc BDSI
Common Stock
2021-05-12 Buy 100,000 $3.24 324,000
Biodelivery Sciences International Inc BDSI
Common Stock
2021-05-11 Buy 150,000 $3.16 474,000
showing 20 of 178 most recent transactions
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com